CLINICAL RESEARCH
Trabecular bone score and 3D-DXA in young, antiretroviral treatment-naïve patients in Madrid
1
Division of Infectious Diseases, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
2
Metabolic Bone Diseases Unit, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
3
Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz. Universidad Autónoma de Madrid, Madrid, Spain
Submission date: 2021-02-01
Final revision date: 2021-03-03
Acceptance date: 2021-03-21
Publication date: 2021-05-05
Arch Med Sci Civil Dis 2021;6(1):52-60
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Low bone mineral density (BMD) has been described as a non-AIDS-related event in human immunodeficiency virus (HIV)-patients, but it is poorly studied by dual-energy X-ray absorptiometry (DXA) and trabecular bone score (TBS) in young HIV-infected men who have received no previous antiretroviral treatment (ART).
Material and methods:
A retrospective study of 56 naïve-HIV-infected men under 50 years old with recently diagnosed HIV infection, between May 2012 and July 2017.
Results:
The mean age was 33.11 ±6.6 years, and they were 56.4% Caucasian and 43.6% Latin American. Regarding lifestyle and risk factors, 57% had previous exposure to tobacco and 31% reported drug use. Low BMD (Z-score < –2.0) was found in 21.4% of the patients, and partially degraded and degraded in 25% and 1.7%, respectively in TBS. We find significative prevalence of bone involvement among naïve HIV-infected men under 50 years old.
Conclusions:
Further studies are necessary to evaluate if BMD assessment should be recommended in young HIV-infected patients.
Low bone mineral density (BMD) has been described as a non-AIDS-related event in human immunodeficiency virus (HIV)-patients, but it is poorly studied by dual-energy X-ray absorptiometry (DXA) and trabecular bone score (TBS) in young HIV-infected men who have received no previous antiretroviral treatment (ART).
Material and methods:
A retrospective study of 56 naïve-HIV-infected men under 50 years old with recently diagnosed HIV infection, between May 2012 and July 2017.
Results:
The mean age was 33.11 ±6.6 years, and they were 56.4% Caucasian and 43.6% Latin American. Regarding lifestyle and risk factors, 57% had previous exposure to tobacco and 31% reported drug use. Low BMD (Z-score < –2.0) was found in 21.4% of the patients, and partially degraded and degraded in 25% and 1.7%, respectively in TBS. We find significative prevalence of bone involvement among naïve HIV-infected men under 50 years old.
Conclusions:
Further studies are necessary to evaluate if BMD assessment should be recommended in young HIV-infected patients.
REFERENCES (26)
1.
Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public health perspective. Am J Public Health 2012; 102: 1516-26.
2.
Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617-23.
3.
Haskelberg H, Carr A, Emery S. Bone turnover markers in HIV disease. AIDS Rev 2011; 13: 240-50.
4.
Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499-504.
5.
Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density. AIDS 2011; 24: 2337-45.
6.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
7.
Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS): a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2013; 98: 1963-70.
8.
Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3580-94.
9.
Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 2014; 29: 518-30.
10.
McCloskey EV, Odén A, Harvey NC, et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 2016; 31: 940-8.
11.
World Health Organization. Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO. Technical report series. Ginebra. Suiza 1994.
12.
2019 ISCD Official Positions – Adult – International Society for Clinical Densitometry (ISCD). Available at: http://www.iscd.org/official-p... October 28, 2019].
13.
Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52: 1061-8.
14.
Güerri-Fernández R, Molina D, Villar-García J, et al. Brief Report: HIV Infection Is Associated with Worse Bone Material Properties, Independently of Bone Mineral Density. J Acquir Immune Defic Syndr 2016; 72:314–8.
15.
Güerri-Fernandez R, Vestergaard P, Carbonell C, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 2013; 28: 1259-63.
16.
Prieto-Alhambra D, Güerri-Fernández R, De Vries F, et al. HIV infection and its association with an excess risk of clinical fractures. JAIDS J Acquir Immune Defic Syndr 2014; 66: 90-5.
17.
Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-74.
18.
Ciullini L, Pennica A, Argento G, et al. Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients. J Bone Miner Metab 2018; 36: 111-8.
19.
Paccou J, Viget N, Drumez E, Cortet B, Robineau O. Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men. Médecine Mal Infect 2018; 48: 442-8.
20.
Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral therapy, especially efavirenz, is associated with low bone mineral density in HIV-infected South Africans. PLoS One 2015; 10: e0144286.
21.
Güerri-Fernández R, Lerma-Chippirraz E, Fernandez Marron A, et al. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. AIDS Lond Engl 2018; 32: 913-20.
22.
Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS 2014; 28: 345-53.
23.
Fonollà R, Nogues X, Malouf J, Romera J HL. Datos de referencia para medidas del hueso cortical y trabecular mediante la tecnología 3D-DXA. SEIOMM 2016; 8: 29.
24.
Kužma M, Vaňuga P, Ságova I, et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 2019; 180: 201-11.
25.
García Hoyos M, Humbert L, Salmón Z, Riancho JA, Valero C. Analysis of volumetric BMD in people with Down syndrome using DXA-based 3D modeling. Arch Osteoporos 2019; 14: 98.
26.
Ceballos ME, Carvajal C, Jaramillo J, Dominguez A, González G. Vitamin D and bone mineral density in HIV newly diagnosed therapy-naive patients without any secondary causes of osteoporosis. Calcif Tissue Int 2019; 104: 42-9.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
